Trandate

Trandate Drug Interactions

labetalol

Manufacturer:

Aspen

Distributor:

Zuellig Pharma
Full Prescribing Info
Drug Interactions
The hypotensive effect of labetalol may be reduced when used in combination with prostaglandin synthetase inhibitors (NSAIDs). Dosage adjustments may therefore be necessary. Additive synergism may occur with other antihypertensive agents.
Labetalol fluoresces in alkaline solution at an excitation wavelength of 334 nanometres and a fluorescence wavelength of 412 nanometres and may therefore interfere with the assays of certain fluorescent substances including catecholamines.
The presence of labetalol metabolites in the urine may result in falsely elevated levels or urinary catecholamines, metanephrine, normetanephrine, and vaillylmandelic acid (VMA) when measured by fluorimetric or photometric methods. In screening patients suspected of having a pheochromocytoma and being treated with labetalol hydrochloride, a specific method, such as a high performance liquid chromatographic assay with solid phase extraction should be employed in determining levels of catecholamines.
Labetalol has been shown to reduce the uptake of radioisotopes of metaiodobenzylguanidine (MIBG). Care should therefore be taken in interpreting results from MIBG scintigraphy.
Concomitant treatment with calcium antagonists which are dihydropyridine derivates (e.g. nifedipine) may increase the risk of hypotension and may lead to heart failure in patients with latent cardial insufficiency. Digitalis glycosides in combination with beta blockers may increase the arioventricular conduction time. Labetalol may enhance digoxin's effect of reducing ventricular rate.
Concomitant administration of labetalol with adrenaline may result in bradycardia and hypertension (see Precautions).
Care should be taken if labetalol is used concomitantly with either Class I antiarrhythmic agents or calcium antagonists of the verapamil type.
Increased risk of myocardial depression in combination with Class I antiarrhythmics (e.g. disopyramide and quinidine) and amiodarone (Class II antiarrhythmics).
Risk of marked bradycardia and hypotension in combination with calcium antagonists with negative inotropic effect (e.g. verapamil, diltiazem). Especially in patients with impaired ventricular function and/or conduction disorders. In case of change from a calcium antagonist to a beta blocker or reverse, new intravenous therapy must not be initiated before at least 48 hours after withdrawal of the former treatment.
Beta blockers, especially non-selective beta blockers, may increase the risk of hypoglycemia in diabetic patients and mask the symptoms of hypoglycemia such as tachycardia and tremor, and delay the normalisation of blood sugar after insulin-induced hypoglycemia, especially non-selective beta blockers. Dose adjustments of oral antidiabetics and insulin may be necessary.
Care should be taken at general anaesthesia of patients using beta blockers. Beta blockers reduce the risk of arrhythmias during anaesthesia, but may lead to reduction of the reflectoric tachycardia and increase the risk of hypotension during anaesthesia. An anaesthetic agent with a low as possible degree of negative inotropic effect should be used. Heart function must be closely monitored and bradycardia due to vagal dominance should be corrected with intravenous administration of atropine, 1-2 mg intravenously (withdrawal prior to surgery, see Dosage & Administration).
For withdrawal in patients using both beta blockers and clonidine, gradual discontinuation of the beta blocker must be done several days before discontinuation of clonidine. This is to reduce the potential rebound hypertensive crisis which is a consequence of withdrawal of clonidine. Accordingly, when changing from clonidine to a beta blocker it is important to discontinue clonidine gradually, and start treatment with the beta blocker several days after clonidine has been withdrawn.
Concomitant administration of labetalol with cholinesterase inhibitors may increase the risk of bradycardia.
Concomitant treatment with alpha stimulating adrenergics may increase the risk of increased blood pressure (e.g. phenylpropanolamine and adrenaline), while concomitant treatment with beta stimulating adrenergics results in a mutual reduced effect (antidote effect).
Concomitant use of ergotamine derivates may increase the risk of vasospastic reactions in some patients.
Labetalol has been shown to increase the bioavailability of imipramine by more than 50% through the inhibition of its 2-hydroxylation. Labetalol in combination with imipramine may increase the effect of imipramine and concomitant use of tricyclic antidepressants.
Concomitant use of tricyclic anti-depressants may increase the incidence of tremor.
Tablet: Cimetidine may increase the bioavailability of labetalol and care is required in the oral dosing of the latter. Enhanced blood pressure reduction may occur in case of concomitant use of e.g. nitrates, antipsychotics (fentiazine derivates such as chloropromazine) and other antipsychotics, antidepressants.
Injection: Labetalol may enhance the hypotensive effects of volatile anaesthetics.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in